期刊文献+

表面健康人群氨基末端B型利钠肽参考范围调查 被引量:66

NT-proBNP concentration in Chinese apparently healthy individuals
原文传递
导出
摘要 目的初步建立适合国人表面健康人群的氨基末端B型利钠肽(NTproBNP)的参考范围。方法体格检查和相关的实验室检查均无异常的表面健康人群共587名(男288名,女299名),按性别各分为<45岁、45~54岁、55~64岁、65~74岁和≥75岁5个年龄组。检测采用Elecsys2010电化学发光免疫分析仪和相应的检测试剂、校准品和质控品以及检测参数检测血清NTproBNP值并评价检测方法。结果NTproBNP的批内和天间的检测精密性良好,符合临床使用要求。表面健康人群NTproBNP水平随年龄增高呈逐渐上升趋势(P<0.05)。NTproBNP的参考范围在<65岁的女性组为<107ng/L,男性组为<78ng/L,≥65岁的女性组为<220ng/L,男性组为<148ng/L;在75岁以下各年龄组,女性NTproBNP水平显著高于男性(P<0.01)。结论国人表面健康人群的NTproBNP水平明显低于国外(欧美)人群。建立一个适合于国人的NTproBNP参考范围有重要的临床应用价值。 Objective To establish the distribution of peptide (NT-proBNP) by age and gender in apparently healthy automated Roche NT-proBNP assay was evaluated, and NT-proBNP serum N-terminal pro-brain natriuretic individuals-based study. Method The t and medical record review in 587 apparently healthy individuals (299 female and 288 male)were performed. Result The automated Roche NT-proBNP assay has good analytical performance. Within the apparently healthy individuals, the distribution of NT-proBNP differed by age and gender, and was higher in female than male ( P 〈 0. 01 ) under 75. The reference range of NT-proBNP was 〈 107 ng/L for women and 〈 78 ng/L for men aged 〈 65 years, and 〈220 ng/L for women and 〈 148 ng/L for men aged ≥65 years, which were lower than the data came from Western people. Conclusion Age,gender and ethnic NT-proBNP differences were demonstrated. Interpretation of NT-proBNP should include consideration of age-, gender-, and ethnic-specific partition values,
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2006年第1期23-26,共4页 Chinese Journal of Laboratory Medicine
基金 上海市心血管临床医学中心建设资助项目(ZX02B06) 教育部211工程重点学科建设资助项目
  • 相关文献

参考文献16

  • 1Bozkurt B,Mann DL. Use of biomarkers in the management of heart failure. Are we there yet? Circulation ,2003,107 : 1231-1233.
  • 2White HD,French JK. Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol,2003,42 : 1917-1920.
  • 3Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure. European Society of Cardiology. Euro Heart J,2001,22 : 1527-1560.
  • 4Hunt SA,Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation ,2005,112 :e154-e235.
  • 5de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet ,2003,362:316-322.
  • 6Yeo KTJ, Wu AHB, Apple FS, et al. Muhicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta,2003,338 : 107-115.
  • 7Vasan RS. Expanding indications for natriuretic peptides:impottance of better new (research) protocols. Am Heart J ,2004,148:743-746.
  • 8Panteghini M,Pagani F,Yeo KTJ,et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem,2004,50:327-332.
  • 9Jaffe AS, Katus H. Acute coronary syndrome biomarkers: the need for more adequate reporting. Circulation ,2004,110 : 104-106.
  • 10Redfield MM, Rodeheffer R J, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration : impact of age and gender. J Am Coll Cardiol,2002 ,40 :976-982.

同被引文献650

引证文献66

二级引证文献640

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部